Wilms tumor protein-derived peptide-MHC complex (WT1-pMHC)

Wilms tumor protein (WT1) is a zinc-finger transcription factor essential for embryonic development, particularly in the urogenital system, but is postnatally restricted to low levels in specific tissues like the kidney and bone marrow [1]. In many cancers, including acute myeloid leukemia and various solid tumors, WT1 is significantly overexpressed and acts as an oncogene [2]. The therapeutic target is the complex formed when intracellular WT1 is degraded into peptides and presented on the cell surface by Major Histocompatibility Complex (MHC) molecules, typically HLA-A*02:01 [4]. This peptide-MHC (pMHC) complex serves as a specific flag for the immune system, allowing T-cells to distinguish malignant cells from healthy ones [4]. Drugs targeting this complex include peptide vaccines like Galinpepimut-S that prime the patient's own immune system and adoptive cell therapies using T-cells engineered with WT1-specific receptors [3,4]. Additionally, bispecific antibodies and TCR-mimetic molecules are being developed to bridge T-cells directly to the WT1-pMHC complex on tumor cells [3]. Because WT1 is ranked as a top priority cancer antigen by the National Cancer Institute, it remains a focal point for developing precision immunotherapies [2].

Other names

WT1 peptide-HLA complexWilms tumor 1 antigen-MHC complexWT1-MHC class I complexWT1-HLA-A*02:01 complexWT1-derived epitope

Induction of T-cell mediated cytotoxicity through the recognition of WT1 peptide-MHC complexes by T-cell receptors (TCRs) or TCR-mimetic agents.